Table 1

Baseline characteristics of the study participants

Control group
n=57
Intervention group
n=54
Sex—% female7561
Age—years56 (13)58 (14)
Symptom duration—months5.3 (3.2)5.0 (2.8)
Rheumatoid factor positive—%7065
Anti-CCP antibody positive—%6059
Current smoker—%3026
Former smoker—%3224
DAS444.4 (1.3)4.3 (1.0)
HAQ1.5 (0.8)1.5 (0.7)
44 swollen joint count10 (7)9 (5)
Ritchie articular index20 (14)20 (12)
Patient global assessment—100 mm VAS56.4 (28.0)54.4 (21.4)
Physician global assessment—Likert 0–53.3 (0.7)3.2 (0.6)
Pain—100 mm VAS52 (25)46 (19)
ESR—mm/h39 (32)35 (25)
CRP—mg/L39 (57)35 (40)
EuroQoL5D-3L Index0.4 (0.4)0.3 (0.4)
MRI RAMRIS score
 Erosions—median (IQR)3.5 (1.5, 6.0)4.0 (1.5, 6.8)
 Synovitis—median (IQR)11.0 (6.5, 14.5)11.5 (8.5, 14.5)
 Osteitis—median (IQR)2.5 (1.0, 7.5)4.0 (1.5, 7.0)
Modified sharp score
 Erosion score—median (IQR)1.5 (0.5, 2.8)1.5 (1.0, 3.0)
 Joint space narrowing—median (IQR)0.0 (0.0, 1.3)0.0 (0.0, 3.5)
 Total sharp score—median (IQR)2.0 (0.8, 4.5)1.5 (1.0, 7.0)
  • Unless otherwise stated values are mean (SD).

  • CRP, C reactive protein; DAS44, 44 joint disease activity score; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; VAS, visual analogue score.